AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors 30 Sep - NSVR & Associates LLP resigned as statutory auditor effective September 29, 2026.
Source: Bse
Vineet Laboratories Limited (VINEETLAB)
Small CapPharma stocks · Small cap · NSE
Vineet Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result25 Aug, 07:52 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
75BullishSMA20 -1.8% / mo · MACD + · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 60
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
VINEETLABD candles · FIT view-8.8%Latest close ₹38.70 on 2026-10-19
Bar
-2.3%
RSI
60
MACD hist
0.32
52W pos
69%
2026-10-19O ₹39.60H ₹39.60L ₹38.25C ₹38.70Vol 54,823 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
VINEETLABNifty PharmaNifty 500
- VINEETLAB
- +3.1%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +8.6 pp
Chart stats
19 Oct 2026- From 52W high
- -11.0%
- 52W range position
- 69%
- ATR (14)
- 5.3%
- Volume vs 20D
- 0.40x
- Avg traded value
- ₹0.5 Cr
- 20D price channel
- ₹34.1 - ₹41.3
₹43.5
₹28 - ₹43.5
₹2
Latest completed session
20-session average
34.2% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Verify management risk first
Do not let cheap valuation override weak Trust or governance evidence.
U-Score
Legacy · OVERVALUED4
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good55
Revenue +34.2% · PAT NDF YoY
Technical
Bullish75
Price trend and sector-relative-strength timing.
Valuation
Legacy model-1551.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence42
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Good · 55/100Rev +34% YoY · margin expansion · +21% QoQ
Filed 25 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹18.9 Cr | +34.2% | +20.7% |
| EBITDA | ₹2.5 Cr | +122.6% | +0.4% |
| Operating margin | 13.2% | +9159 bps | -267 bps |
| PAT | ₹0.7 Cr | NDF | -14.1% |
| PAT margin | 3.9% | +7865 bps | -157 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 65.00
- P/B
- 1.58
- EV/EBITDA
- 10.78
- Market Cap
- 72.20Cr
Profitability
- ROE
- 3.68%
- ROCE
- 8.49%
- ROA
- 0.89%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -25.00%
- EPS 5Y
- -9.00%
- Revenue 3Y
- -35.00%
- EPS 3Y
- -4.00%
Balance Sheet
- Debt/Equity
- 0.99
- Interest Coverage
- 1.74×
- Altman Z
- 1.68
- Book Value
- 23.80
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- -12.03 Cr
- EPS TTM
- 0.58
Shareholding
- Promoter Hold
- 5.98%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 61%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 18.9+20.7% vs prev
Net Profit
₹ CrLatest: 0.7-14.1% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 60. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~1.8% over last month) — short-term momentum negative.
- RSI(14) at 60 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 11% off 52W high · 38% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
65
RS percentile
Stage 2 UptrendRecent S2
1M return
+5.2%
3M return
+3.1%
6M return
-3.2%
1Y return
+2.2%
RS 1D
0
RS 20D
-5
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 8.5% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +2.5%.
50-DMA
price above
200-DMA
price above
S2 entered
29 Sept 2026
S2 age
14 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 133.49+0.23%
RS vs Nifty 500133
Valuation & peers
U-Score 4 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 4 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Distress Watch
Fundamental score breakdown
U band · OVERVALUEDValuation4/30
Growth5/25
Quality0/20
Balance Sheet0/15
Cash Flow2/10
Piotroski
3/9 (+1)
Penalties
-8
Raw sum
4
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
4/100 · legacy band OVERVALUED
Positive drivers
- Growth contributes 5/25 to the score.
- Cash flow contributes 2/10 to the score.
- Valuation contributes 4/30 to the score.
Main drags
- Altman Z is 1.7, in distress territory.
- Penalty bucket subtracts 8 points.
- Fair-value margin of safety is negative at -1551.5%.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
65.0
PB
1.6
EV/EBITDA
10.8
ROE
3.7%
ROCE
8.5%
FCF Yield
—
Debt/Equity
1.0
MoS
-1551.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
4
Previous: 5 (-1)
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1551.5%
Previous: -1551.5%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
5
5
5
5
5
5
5
5
5
5
5
5
Factor attribution
Valuation
4-1
was 5
Modelled fair value
Graham Number
₹17.62
-119.6% MoS
Growth-justified P/E
4.0
Growth-justified Value
₹2.34
-1551.5% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
VIVIMEDLAB
Small
Vivimed Labs Limited
Healthcare Services
match 164
13
—
—
—
OVERVALUED
MANGALAM
Small
Mangalam Drugs And Organics Limited
Healthcare Services
match 164
2
—
-35.2%
—
OVERVALUED
MAXHEALTH
Large
Max Healthcare Institute Limited
Healthcare Services
match 152
35
67.5
12.7%
-497%
WATCHLIST
NATCAPSUQ
Small
Natural Capsules Limited
Healthcare Services
match 150
52
13.5
6.5%
+71%
FAIR VALUE
LOTUSEYE
Small
Lotus Eye Hospital and Institute Limited
Healthcare Services
match 149
13
1504.0
0.1%
-161992%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Vineet Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
42Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 1st percentile of the scored universe and 1st percentile within Pharma. Main check: results consistency is weak at 19/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
8 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
1st percentile
overall median 67 · Pharma: 1st pctile, median 70 · Small: 2nd pctile, median 66
Evidence depth
Financial-only
8 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Do not rely on management narrative unless hard turnaround evidence is visible.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
48
watch · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
22
weak · leverage and solvency
Discipline
30
weak · capital discipline
Results
19
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is 11%.
Trust risks
- ▸Promoter holding fell 9.9%.
- ▸Debt/equity is 3.07.
- ▸Altman Z is 1.12.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Vineet Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Monitoring Agency Report 14 Aug - Crisil report notes Rs 25.91 lakh misused, later returned; rights issue deployment delayed.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Resignation of Managing Director 21 Jul - Mr. Gaddam Venkata Ramana ceased as Managing Director from July 21, 2026, continuing as director.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Change in Management 21 Jul - Board appoints Rajesh Kumar Kathulla as additional executive director for 5 years from 11 June 2026.
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 29 May - Mr. Ramesh Kumar Bandari resigned as Company Secretary and Compliance Officer, effective May 29, 2026.
Source: Bse
AnnouncementQ3 2026
Q3 2026 · Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 21 Apr - Submitted Regulation 74(5) certificate for Q4 and FY2026; no demat/remat requests received.
Source: Bse
AnnouncementDec 2025
Dec 2025 · Announcement under Regulation 30 (LODR)-Monitoring Agency Report 15 May - Crisil report for Q3 FY26 rights issue proceeds: Rs 1,352.24 lakh utilized, no deviation reported.
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.